Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO‐ADOC study)

Journal of the European Academy of Dermatology and Venereology, Journal Year: 2024, Volume and Issue: 38(11), P. 2149 - 2155

Published: July 17, 2024

Clinical trials and real-life data have reported an increased incidence of conjunctivitis in patients treated with dupilumab for their atopic dermatitis (AD). Although mostly mild severity, some cases will appear or increase after initiation, which can lead to discontinuation.

Language: Английский

---

An Open-Label Prospective Observational Study of Tralokinumab in Atopic Dermatitis Patients with Inadequate Response to Dupilumab

Dermatitis, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 1, 2024

Language: Английский

---

The efficacy of dupilumab in patients affected by atopic dermatitis who previously failed tralokinumab

International Journal of Dermatology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 11, 2024

Biologic drugs and small molecules have completely changed the therapeutic scenario of moderate-to-severe forms atopic dermatitis (AD).1 However, there are still patients unresponsive or partially responsive to these new approaches, leading need for data evaluating effectiveness drug switching.2 Among biologics currently approved AD management, dupilumab is a human monoclonal antibody immunoglobulin G4 subclass, which acts by binding interleukin (IL)4 receptor alpha subunit, shared IL4 IL13 complexes, thus inhibiting signaling cascade both cytokines. Tralokinumab fully IgG4 antibody, specifically binds with high affinity, thereby its interaction receptors neutralizing biological activity this cytokine.1 Although regarding switch from tralokinumab has been consistent,3-5 concerning opposite treatment change scant.6 In context, our study aimed investigate after failure. monocentric, retrospective case series, 15 (8 males, 53.33%, mean age 62.33 ± 12.89 years, duration: 25.20 26.24 years) who previously failed ineffectiveness were subsequently treated at least 16 weeks included. The following scores used evaluate severity: Eczema Area Severity Index (EASI), Pruritus–Numerical Rating Scale (P-NRS), Dermatology Life Quality (DLQI). Patient features severity shown in Table 1. At beginning treatment, EASI, DLQI, P-NRS 24.80 4.86, 20.07 5.23, 7.53 1.68, decreased 17.87 3.62, 12.07 3.43, 5.80 1.52 last follow-up (mean 26.13 5.53 weeks, range 16–38), respectively. None received other systemic treatments interruption except dupilumab. All subjects showed clinical response (last follow-up: EASI: 2.07 1.83; DLQI: 1.20 1.26; P-NRS; 1.07 1.10; 26.27 9.71 [range 16–52]). Of note, all weeks. No adverse events (AEs) collected during either tralokinumab. Finally, no factors such as age, sex, duration, comorbidities, duration correlated better response. To date, real-life switching Our results line experience recently published Tavoletti et al. that demonstrated reduction EASI 22.4 5.26 3 1.56 an average 6.4 months their cohort 11 successfully dupilumab, without AEs reported.6 Moreover, authors reported 50% within 1.7 1.29 (range 1–4) according (50% 1.93 1.03 1–4]).6 Globally, suggest importance targeting multiple cytokines involved pathogenesis, subset could be unique inhibition IL13. Indeed, it should emphasized may inter-individual variability responses versus IL4/IL13 pathway. Certainly, inclusion larger more diverse patient populations allow understanding well assessment impact patient-specific (e.g., disease duration) determining success sum up, valuable alternative tralokinumab, highlighting further studies establish guidelines offer tailored approach. manuscript given written informed consent publication details. Data supporting findings available corresponding author upon reasonable request.

Language: Английский

---

Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study

The Journal of Allergy and Clinical Immunology In Practice, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

---